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a continuous improvement was noted in sustained virological
response, from 13% with IFN monotherapy to 31% with PEG-
IFN +RBV, while even a 48% sustained virological response
has been achieved in the prospective trial. The predictors
of outcome were the 4-week ‘rapid’ and 12-week ‘early’
virological responses, female gender, age, BMI and adher-
ence. The most frequent complications of the treatment
were cytopenia, haemolysis and depression, occurring in 9%
of patients.
Conclusion: Unlike in HBV infection, in HCV hepatitis the
efﬁcacy of antiviral treatment has gradually improved in our
everyday clinical practice. To manage the growing popula-
tions of hard-to-treat patients with chronic viral hepatitis,
there is a need for more effective treatment modalities,
including optimised, individualised dosing and novel antivi-
ral agents.
doi:10.1016/j.ijid.2008.05.1258
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Aims: Since in the outcome of chronic hepatitis C virus
(HCV) infection the progression of hepatic ﬁbrosis is essen-
tial, and interferon (IFN) treatment is supposed to inhibit
ﬁbrogenesis, we wanted to compare changes in three non-
invasive ﬁbrosis markers in chronic HCV hepatitis.
Methods: Plasma levels of TGF-beta1 and hyaluronic acid
(HA) were determined by ELISA, procollagen-III-peptide (P-
III-P) levels by RIA in 49 patients with chronic hepatitis C
before the antiviral treatment and 1, 3, 6 and 12 months
thereafter. Twenty two patients became responders (R), 27
patients were non-responders (NR). Thirty healthy controls
were also studied. Correlation between TGF-beta1, HA, P-
III-P levels and the histological activity and the ﬁbrosis score
in liver biopsy was evaluated.
Results: Pretreatment plasma TGF-beta1, HA and P-
III-P levels were signiﬁcantly (p < 0,01) increased in both
responder and non-responder patients compared to con-
trols. HA levels correlated with ﬁbrosis score, TGF-beta1
with histological activity index. PEG-IFN + ribavirin treat-
ment decreased both TGF-beta1 and HA levels, not only
in responders but also in non-responders. The reduction of
ﬁbrosis marker levels was more considerable after 6 months
of antiviral therapy, and remained sustained even 6 months
after the treatment. No correlation was found betwen ﬁbro-
sis markers and HCV RNA levels.
Conclusion: PEG-IFN plus Ribavirin treatment decreased
TGF-beta1 and hyaluronic acid levels independently of
virological response. These data suggest that antiviral
treatment may have antiﬁbrotic effect even in virological
non-responders.
doi:10.1016/j.ijid.2008.05.1259
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Infections with HBV and HCV are the most common cause
of chronic hepatitis and their consequence may be liver cir-
rhosis and/or hepatocellular carcinoma. Co-infection with
these viruses is relatively common and it remains serious
epidemiological and clinical problem.
Objective: Evaluation of impact of co-infection with HBV
and HCV on clinical picture of chronic hepatitis.
Material and Methods: retrospective analysis of 238
patients among 1330 patients hospitalized in years
2001—2005 in Department of Infectious Diseases in Wro-
claw due to diagnostics of chronic hepatitis C. Patients
were divided into groups according to their serological sta-
tus: group A - anti-HCV positive, anti-HBc negative patients
(n = 123), group B - anti-HCV positive, anti-HBc positive,
HBsAg negative patients (n = 115). Groups A and B were
randomly selected according to age, sex, duration of HCV
infection. Some biochemical features, histological pattern
(modiﬁed HAI scale) and virological status were evaluated.
Dates were statistical analyzed by chi-square Wald test.
Results: Median value of viral load in group A was
1,4× 106 and in group B was 1,0× 106 (p > 0,05). There were
no statistical correlation of GOT, GPT, GGTP and PLT values
in these two groups. Grading in group A was 1,64 and in
group B was 1,62 (p > 0,5). Relevant differences in ﬁbrosis
stage was observed between the groups - staging in group A
was 1,87 and in group B 1,37 (p < 0,05)).
Conclusions: Past HBV infection and possible minireplica-
tion has no impact on HCV viremia. Fibrosis of the liver was
surprisingly higher in HCV monoinfection patients. Further
investigation in large and homogenous groups of patients are
needed.
doi:10.1016/j.ijid.2008.05.1247
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Background: Current therapy for HCV consists of a com-
bination of synthetically-modiﬁed interferon, pegylated
interferon, and ribavirin, to which nearly 50% of patients
do not respond. Clinical trials have demonstrated that this
